Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCB053914 + ruxolitinib
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
INCB053914 + ruxolitinib is a **combination therapy** under clinical investigation for the treatment of advanced malignancies and myeloproliferative neoplasms (MPNs). INCB053914 is a pan-PIM kinase inhibitor, targeting all three PIM kinases (PIM1, PIM2, PIM3), which are serine/threonine kinases involved in regulating apoptosis and cellular proliferation. Ruxolitinib is a selective inhibitor of Janus kinase 1 and 2 (JAK1, JAK2), which regulates cytokine-mediated signaling pathways in hematologic and inflammatory diseases. Combination of these agents has shown **synergistic effects on suppression of neoplastic cell growth, induction of apoptosis**, and inhibition of persistent myeloproliferation in JAK2-driven preclinical models and patient sample assays. This combination is being developed and clinically tested for improved outcomes in patients with **MPNs, polycythemia vera, essential thrombocythemia, and primary myelofibrosis**[1][2][3][4][5][6].
- Other names
- INCB053914 + Jakafi
02
Targets
JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)PIM2 (Proto-oncogene serine/threonine-protein kinase Pim2)PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)RPS6KA3 (RSK2)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on INCB053914 + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCB053914 + ruxolitinib.